Recursion Pharmaceuticals, Inc. RXRX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$559.78M+2.6% | -$644.76M-39.1% | -$715.54M-89.4% | -$649.13M-73.1% | -$574.78M-62.3% | ||
| $84.04M+73.5% | $83.7M+129% | $77.17M+148% | $63.33M+101% | $48.45M+72.7% | ||
| $97.38M-4.2% | $111.22M+36.2% | $118.24M+76.5% | $111.25M+69.8% | $101.62M+67.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$4.5M— | ||
| —— | —— | $1.09M+154% | $5.46M— | $8.96M— | ||
| —— | —— | —— | —— | —— | ||
| -$43.68M— | -$33.78M— | -$31.88M— | -$24.48M— | —— | ||
| —— | —— | —— | -$31.94M-424% | -$21.72M-785% | ||
| -$29.26M— | -$36.77M— | -$35.68M— | —— | —— | ||
| -$320.95M+17.5% | -$371.81M-3.5% | -$441.17M-38.8% | -$383.03M-15.5% | -$388.83M-22.8% | ||
| $4.9M-44.8% | $6.47M-52.8% | $6.52M-54.9% | $10.84M+1.8% | $8.87M-33.9% | ||
| $2.81M+181% | $3.81M— | $3.81M— | $1.5M— | $1M— | ||
| —— | —— | —— | —— | -$4.44M— | ||
| —— | —— | —— | $2.51M-26.9% | $3.35M+675% | ||
| -$9.94M-104% | -$16.87M-106% | $259.83M+1,553% | $257.82M+1,986% | $259.44M+2,348% | ||
| $8.59M+32.9% | $8.43M+89.8% | $8.36M+176% | $8.52M+1,006% | $6.46M+741% | ||
| $487.84M+47.6% | $528.86M+76.0% | $406.51M+10.6% | $169.02M-57.8% | $330.57M+138% | ||
| $477.54M+44.4% | $521.53M+71.5% | $400.17M+7.0% | $165.29M-59.8% | $330.75M+117% | ||
| $9.38M+470% | $18.04M+630% | $12.49M+6,471% | $11.02M— | $1.65M— | ||
| $156.02M— | $150.9M— | $231.31M— | —— | —— | ||
| —— | —— | —— | —— | -$4.5M— | ||
| —— | —— | —— | —— | —— | ||
| -$18.88M-7.6% | -$19.99M-28.3% | -$20.59M-57.9% | -$20.07M— | -$17.55M— | ||
| —— | —— | —— | —— | —— | ||
| -$43.68M— | -$33.78M— | -$31.88M— | -$24.48M— | —— | ||
| -$22.73M— | -$49.86M— | -$17.91M— | —— | —— | ||
| —— | —— | —— | -$31.94M-424% | -$21.72M-659% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $2.51M-26.9% | $3.35M+675% | ||
| —— | —— | —— | —— | -$4.44M— | ||
| —— | —— | —— | —— | —— | ||
| $8.59M+32.9% | $8.43M+89.8% | $8.36M+176% | $8.52M— | $6.46M— | ||
| —— | —— | —— | —— | —— | ||
| -$29.26M— | -$36.77M— | -$35.68M— | —— | —— | ||
| $1.92M-57.4% | $0-100% | $1.5M-66.7% | $3M0.0% | $4.5M— | ||
| $21.36M+5.4% | $22.25M+33.9% | $22.48M+70.3% | $22.8M+136% | $20.27M+137% | ||
| —— | —— | —— | —— | —— | ||
| -$325.85M+18.1% | -$378.28M-1.5% | -$447.69M-34.7% | -$393.87M-15.1% | -$397.71M-20.4% | ||
| -$325.85M+18.1% | -$378.28M-1.5% | -$447.69M-34.7% | -$393.87M-15.1% | -$397.71M-20.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Recursion Pharmaceuticals, Inc. generate?
- Recursion Pharmaceuticals, Inc. (RXRX) generated -$321.0M in operating cash flow over the trailing twelve months.
- What is Recursion Pharmaceuticals, Inc.'s free cash flow?
- After $4.9M of capital expenditures, Recursion Pharmaceuticals, Inc.'s free cash flow was -$325.8M over the trailing twelve months, up 18.1% year over year.
- Where does Recursion Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Recursion Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
